The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Exciting upcoming MPNs trials: V617F-targeted JAK2 inhibitors and anti-calreticulin antibodies
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, highlights upcoming clinical trial results in myeloproliferative neoplasms (MPNs). He mentions trials of JAK2 inhibitors targeting the V617F mutation, which aim for better efficacy with fewer toxicities. Additionally, trials of monoclonal antibodies against calreticulin are being conducted with the goal of eradicating the disease and achieving a cure. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
